Warner J.O., Kaliner M.A., Crisci C.D., Del Giacco S., Frew A.J., Liu G.H., et al. Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Int Arch Allergy Immunol. 2006;139:166–74. doi: 10.1159/000090502..
DOI: 10.1159/000090502
Weinberg E.G. The WAO white book on allergy 2011-2012: review article. Curr Allergy Clin Immunol. 2011;24(3):156–7.
Pawankar R.C.G., Holgate S.T. World allergy organization (WAO) white book on allergy. Update. 2013;248. doi: 10.1186/1939-4551-6-3..
DOI: 10.1186/1939-4551-6-3
Nitin J., Palagani R., Shradha N.H., Vaibhav J., Kowshik K., Manoharan R., et al. Prevalence, severity and risk factors of allergic disorders among people in south India. Afr Health Sci. 2016;16:201–209. doi: 10.4314/ahs.v16i1.27..
DOI: 10.4314/ahs.v16i1.27
Hannah J., Gould H.J., Sutton B.J. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205-217. doi: 10.1038/nri2273..
DOI: 10.1038/nri2273
Siracusa M.C., Kim B.S., Spergel J.M., Artis D. Basophils and allergic inflammation. J Allergy Clin Immunol. 2013;132:789-801. doi: 10.1016/j.jaci.2013.07.046..
DOI: 10.1016/j.jaci.2013.07.046
Cameron L., Christodoulopoulos P., Lavigne F., Nakamura Y., Eidelman D., McEuen A., et al. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J Immunol. 2000;164:1538-1545. doi: 10.4049/jimmunol.164.3.1538..
DOI: 10.4049/jimmunol.164.3.1538
Muramatsu M., Kinoshita K., Fagarasan S., Yamada S., Shinkai Y., Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553-563. doi: 10.1016/s0092-8674(00)00078-7..
DOI: 10.1016/s0092-8674(00)00078-7
Pène J., Rousset F., Brière F., Chrétien I., Bonnefoy J.Y., Spits H., et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S A. 1988;85:6880-6884. doi: 10.1073/pnas.85.18.6880..
DOI: 10.1073/pnas.85.18.6880
Luger E.O., Fokuhl V., Wegmann M., Abram M., Tillack K., Achatz G., et al. Induction of longlived allergen-specific plasma cells by mucosal allergen challenge. J Allergy Clin Immunol. 2009;124:819-826.e4. doi: 10.1016/j.jaci.2009.06.047..
DOI: 10.1016/j.jaci.2009.06.047
Erazo A., Kutchukhidze N., Leung M., Christ A.P., Urban J.F. Jr, Curotto de Lafaille M.A., et al. Unique maturation program of the IgE response in vivo. Immunity. 2007;26:191-203. doi: 10.1016/j.immuni.2006.12.006..
DOI: 10.1016/j.immuni.2006.12.006
Suh K.S., Park H.S., Nahm D.H., Kim Y.K., Lee Y.M., Park K. Role of IgG, IgA, and IgE antibodies in nasal polyp tissue: their relationships with eosinophilic infiltration and degranulation. J Korean Med Sci. 2002;17:375-380. doi: 10.3346/jkms.2002.17.3.375..
DOI: 10.3346/jkms.2002.17.3.375
Sheahan P., Ahn C.N., Harvey R.J., Wise S.K., Mulligan R.M., Lathers D.M., et al. Local IgE production in nonatopic nasal polyposis. J Otolaryngol Head Neck Surg. 2010;39(1):45-51. Available at: https://europepmc.org/abstract/med/20122344.https://europepmc.org/abstract/med/20122344
Sheahan P., Ahn C.N., Harvey R.J., Wise S.K., Mulligan R.M., Lathers D.M., et al. Local IgE production in nonatopic nasal polyposis. J Otolaryngol Head Neck Surg. 2010;39(1):45-51. Available at: https://europepmc.org/abstract/med/20122344.https://europepmc.org/abstract/med/20122344
Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623– 2632. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8360482.https://www.ncbi.nlm.nih.gov/pubmed/8360482
Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623– 2632. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8360482.https://www.ncbi.nlm.nih.gov/pubmed/8360482
Corren J., Busse W., Meltzer E.O., Mansfield L., Bensch G., Fahrenholz J., et al. A randomized, controlled, phase 2 study of AMG 317, an IL4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010;181:788-96. doi: 10.1164/rccm.200909-1448oc..
DOI: 10.1164/rccm.200909-1448oc
Incorvaia C., Mauro M., Riario-Sforza G.G., Frati F., Tarantini F., Caserini M. Current and future applications of the anti-IgE antibody omalizumab. Biologics. 2008;2(1):67–73. doi: 10.2147/btt.s1800..
DOI: 10.2147/btt.s1800
Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455-66. doi: 10.1056/nejmoa1304048..
DOI: 10.1056/nejmoa1304048
Kimura S., Pawankar R., Mori S., Nonaka M., Masuno S., Yagi T., et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res. 2011;3:186-93. doi: 10.4168/aair.2011.3.3.186..
DOI: 10.4168/aair.2011.3.3.186
Gauvreau G.M., O’Byrne P.M., Boulet L.P., Wang Y., Cockcroft D., Bigler J., et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102-2110. doi: 10.1056/nejmoa1402895..
DOI: 10.1056/nejmoa1402895
Zheng L., Li B., Qian W., Zhao L., Cao Z., Shi S., et al. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochem Biophys Res Commun. 2008;375:619–622. doi: 10.1016/j.bbrc.2008.08.055..
DOI: 10.1016/j.bbrc.2008.08.055
Eggel A., Baravalle G., Hobi G., Kim B., Buschor P., Forrer P., et al. Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol. 2014;133:1709–19 e1708. doi: 10.1016/j.jaci.2014.02.005..
DOI: 10.1016/j.jaci.2014.02.005
Chang T.W., Wu P.C., Hsu C.L., Hung A.F. AntiIgE antibodies for the treatment of IgEmediated allergic diseases. Adv Immunol. 2007;93:63–119. doi: 10.1016/s0065-2776(06)93002-8..
DOI: 10.1016/s0065-2776(06)93002-8
Holgate S., Bousquet J., Wenzel S., Fox H., Liu J., Castellsague J. Efficacy of omalizumab, all anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthmarelated morbidity and mortality. Curt Med Res Opin. 2001;17(4):233–40. doi: 10.1185/030079901753403126..
DOI: 10.1185/030079901753403126
Zhou B., Lin B., Li J., Qian W., Hou S., Zhang D., et al. Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects. mAbs. 2012;4:110–19. doi: 10.4161/mabs.4.1.18349..
DOI: 10.4161/mabs.4.1.18349
Kawakami T., Blank U. From IgE to omalizumab. J Immunol. 2016;197:4187–4192. doi: 10.4049/jimmunol.1601476..
DOI: 10.4049/jimmunol.1601476
Tonacci A., Billeci L., Pioggia G., Navarra M., Gangemi S. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature. Pharmacotherapy. 2017;37:464–480. doi: 10.1002/phar.1915..
DOI: 10.1002/phar.1915
Lustgarten J., Eshhar Z. Specific elimination of Ige production using T-cell lines expressing chimeric T-cell receptor genes. Eur J Immunol. 1995;25:2985–2991. doi: 10.1002/eji.1830251041..
DOI: 10.1002/eji.1830251041
Jardieu P.M., Fick R.B. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999;118(2–4):112–115. doi: 10.1159/000024043..
DOI: 10.1159/000024043
Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459-465. doi: 10.1016/j.jaci.2004.11.053..
DOI: 10.1016/j.jaci.2004.11.053
Cox L., Platts-Mills T.A., Finegold I., et al; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–1377. doi: 10.1016/j.jaci.2007.09.032..
DOI: 10.1016/j.jaci.2007.09.032
Nopp A., Johansson S.G., Adédoyin J., Ankerst J., Palmqvist M., Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65(1):56–60. doi: 10.1111/j.1398-9995.2009.02144.x..
DOI: 10.1111/j.1398-9995.2009.02144.x
Ledford D., Busse W., Trzaskoma B., et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162– 169.e2. doi: 10.1016/j.jaci.2016.08.054..
DOI: 10.1016/j.jaci.2016.08.054
Domingo C., Pomares X., Navarro A., et al. A step-down protocol for treatment in oral corticosteroid dependent allergic asthma patients. Br J Clin Pharmacol. 2018;84(2):339– 348. doi: 10.1111/bcp.13453..
DOI: 10.1111/bcp.13453
Vennera Mdel C., Valero A., Uria E., Forne C., Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–578. doi: 10.1007/s40261-016-0402-2..
DOI: 10.1007/s40261-016-0402-2
Suzuki C., Lopes da Silva N., Kumar P., Pathak P., Ong S.H. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20(8):832–839. doi: 10.1080/13696998.2017.1333513..
DOI: 10.1080/13696998.2017.1333513
Zafari Z., Sadatsafavi M., Mark FitzGerald J.; Canadian Respiratory Research Network. Canadian Respiratory Research Network. Costeffectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc. 2018;30:16–3. doi: 10.1186/s12962-018-0089-8..
DOI: 10.1186/s12962-018-0089-8
Global Initiative for Asthma Report, Global strategy for Asthma Management and Prevention. Available at: https://ginasthma. org/2018-gina-report-global-strategy-forasthma-management-and-prevention/ Accessed May 13, 2018.https://ginasthma
Global Initiative for Asthma Report, Global strategy for Asthma Management and Prevention. Available at: https://ginasthma. org/2018-gina-report-global-strategy-forasthma-management-and-prevention/ Accessed May 13, 2018.https://ginasthma
Zafari Z., Sadatsafavi M., Marra C.A., Chen W., FitzGerald J.M. Cost-Effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma. PLoS One. 2016;11(1):e0146003. doi: 10.1371/journal.pone.0146003..
DOI: 10.1371/journal.pone.0146003
Tatar M., Sezen S., Senturk A., Balp M.M., Saylan M., Keskinaslan A. Costeffectiveness of omalizumab in chronic idiopathic urticarial refractory to H1-antihistamines in Turkey. Value Health. 2014;17(7):A604. doi: 10.1016/j.jval.2014.08.2101..
DOI: 10.1016/j.jval.2014.08.2101
Alhossan A., Lee C.S., MacDonald K., Abraham I. «Real-life» Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362–1370.e2. doi: 10.1016/j.jaip.2017.02.002..
DOI: 10.1016/j.jaip.2017.02.002
Lai T., Wang S., Xu Z. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;3(5):8191. doi: 10.1038/srep08191..
DOI: 10.1038/srep08191
Walker S., Monteil M., Phelan K., Lasserson T.J., Walters E.H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;19(2):CD003559. doi: 10.1002/14651858.cd003559.pub3..
DOI: 10.1002/14651858.cd003559.pub3
Siergiejko Z., Świebocka E., Smith N., et al. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin. 2011;27(11):2223–2228. doi: 10.1185/03007995.2011.620950..
DOI: 10.1185/03007995.2011.620950
Domingo C., Moreno A., Jose Amengual M., Montуn C., Suбrez D., Pomares X. Omalizumab in the management of oral corticosteroiddependent IGE-mediated asthma patients. Curr Med Res Opin. 2011;27(1):45–53. doi: 10.1185/03007995.2010.536208..
DOI: 10.1185/03007995.2010.536208
Barnes N., Menzies-Gow A., Mansur A.H., et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529–536. doi: 10.3109/02770903.2013.790419..
DOI: 10.3109/02770903.2013.790419
Braunstahl G.J., Chen C.W., Maykut R., Georgiou P., Peachey G., Bruce J. The eXpeRience registry: the «real-world» effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. doi: 10.1016/j.rmed.2013.04.017..
DOI: 10.1016/j.rmed.2013.04.017
Normansell R., Walker S., Milan S.J., Walters E.H., Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559. doi: 10.1002/14651858. cd003559.pub4..
DOI: 10.1002/14651858. cd003559.pub4
Cardet J.C., Casale Т.В. New insights into the utility of omalizumab. J Allergy Clin Immunol. 2019;143(3):923-936. doi: 10.1016/j.jaci.2019.01.016..
DOI: 10.1016/j.jaci.2019.01.016
Zhao Z.-T. et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750. doi: 10.1016/j.jaci.2015.12.1342..
DOI: 10.1016/j.jaci.2015.12.1342
Tharp M.D. et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of «realworld» evidence. JAMA dermatology. 2019;155(1):29-38. doi: 10.1001/jamadermatol.2018.3447..
DOI: 10.1001/jamadermatol.2018.3447
Marzano A.V., Genovese G., Casazza G., Fierro M.T., Dapavo P., Crimi N., et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2018;33(5):918-924. doi: 10.1111/jdv.15350..
DOI: 10.1111/jdv.15350
Asero R., Marzano A.V., Ferrucci S., Cugno M. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU. J Allergy Clin Immunol Pract. 2017;5:1740-1742. doi: 10.1016/j.jaip.2017.07.009..
DOI: 10.1016/j.jaip.2017.07.009
Maurer M., Metz M., Brehler R., Hillen U., Jakob T., Mahler V., et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141:638- 49. doi: 10.1016/j.jaci.2017.06.032..
DOI: 10.1016/j.jaci.2017.06.032
Gericke J., Metz M., Ohanyan T., Weller K., Altrichter S., Skov P.S., et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139:1059-61.e1. DOI: 10.1016/j.jaci.2016.07.047.
DOI: 10.1016/j.jaci.2016.07.047
Zuberbier T., Aberer W., Asero R., et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018;73(7):1393-1414. doi: 10.1111/all.13397..
DOI: 10.1111/all.13397
Pawankar R., Mori S., Ozu C., Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy. 2011;1:157-67. doi: 10.5415/apallergy.2011.1.3.157..
DOI: 10.5415/apallergy.2011.1.3.157
Phillips K.M., Hoehle L.P., Caradonna D.S., Gray S.T., Sedaghat A.R. Association of severity of chronic rhinosinusitis with degree of comorbid asthma control. Ann Allergy Asthma Immunol. 2016;117:651-654. doi: 10.1016/j.anai.2016.09.439..
DOI: 10.1016/j.anai.2016.09.439
Leynaert B., Neukirch F., Demoly P., Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106:S201-5. doi: 10.1067/mai.2000.110151..
DOI: 10.1067/mai.2000.110151
Asher M.I., Montefort S., Björkstén B., Lai C.K., Strachan D.P., Weiland S.K., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-743. doi: 10.1016/s0140-6736(06)69283-0..
DOI: 10.1016/s0140-6736(06)69283-0
Bousquet J., Vignola A.M., Demoly P. Links between rhinitis and asthma. Allergy. 2003;58:691-706. doi: 10.1034/j.1398-9995.2003.00105.x..
DOI: 10.1034/j.1398-9995.2003.00105.x
Simons F.E. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol. 1999;104:534-540. doi: 10.1016/s0091-6749(99)70320-9..
DOI: 10.1016/s0091-6749(99)70320-9
Vignola A.M., Chanez P., Godard P., Bousquet J. Relationships between rhinitis and asthma. Allergy. 1998;53:833-839. doi: 10.1111/j.1398-9995.1998.tb03988.x..
DOI: 10.1111/j.1398-9995.1998.tb03988.x
Ziyab A.H. Prevalence and risk factors of asthma, rhinitis, and eczema and their multimorbidity among young adults in Kuwait: a cross-sectional study. Biomed Res Int. 2017;2017:1-10. doi: 10.1155/2017/2184193..
DOI: 10.1155/2017/2184193
Grossman J. One airway, one disease. Chest. 1997;111:11S-6S. doi: 10.1378/chest.111.2_ supplement.11s..
DOI: 10.1378/chest.111.2_ supplement.11s
Brito Rde C., da Silva G.A., Motta M.E., Brito M.C. The association of rhinoconjunctivitis and asthma symptoms in adolescents. Rev Port Pneumol. 2009;15:613-28. doi: 10.1016/s2173-5115(09)70137-x..
DOI: 10.1016/s2173-5115(09)70137-x
Adelroth E., Rak S., Haahtela T., Aasand G., Rosenhall L., Zetterstrom O., et al. Recombinant humanized mAb-E25, an antiIgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253-259. doi: 10.1067/mai.2000.108310..
DOI: 10.1067/mai.2000.108310
Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286:2956-2967. doi: 10.1001/jama.286.23.2956..
DOI: 10.1001/jama.286.23.2956
Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709- 717. doi: 10.1111/j.1398-9995.2004.00550.x..
DOI: 10.1111/j.1398-9995.2004.00550.x
Tabbara K.F. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol. 1999;34:88-92. Available at: https://www. ncbi.nlm.nih.gov/pubmed/10321319.https://www
Tabbara K.F. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol. 1999;34:88-92. Available at: https://www. ncbi.nlm.nih.gov/pubmed/10321319.https://www
Vichyanond P., Pacharn P., Pleyer U., Leonardi A. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol. 2014;25:314-22. doi: 10.1111/pai.12197..
DOI: 10.1111/pai.12197
Bonini S., Bonini S., Lambiase A., Marchi S., Pasqualetti P., Zuccaro O., et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with longterm follow-up. Ophthalmology. 2000;107:1157-63. doi: 10.1016/s0161-6420(00)00092-0..
DOI: 10.1016/s0161-6420(00)00092-0
Sánchez J., Cardona R. Omalizumab. An option in vernal keratoconjunctivitis? Allergol Immunopathol (Madr). 2012;40:319-20. doi: 10.1016/j.aller.2011.08.002..
DOI: 10.1016/j.aller.2011.08.002
de Klerk T.A., Sharma V., Arkwright P.D., Biswas S. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS. 2013;17:305-6. doi: 10.1016/j.jaapos.2012.12.153..
DOI: 10.1016/j.jaapos.2012.12.153
Doan S., Amat F., Gabison E., Saf S., Cochereau I., Just J. Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature. Ophthalmol Ther. 2017;6:195-206. doi: 10.1007/s40123-016-0074-2..
DOI: 10.1007/s40123-016-0074-2
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1-12. doi: 10.4193/rhino50e2..
DOI: 10.4193/rhino50e2
Bachert C., Zhang L., Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136:1431-1440. doi: 10.1016/j.jaci.2015.10.010..
DOI: 10.1016/j.jaci.2015.10.010
Tomassen P., Vandeplas G., Van Zele T., Cardell L.O., Arebro J., Olze H., et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449-1456.e4. doi: 10.1016/j.jaci.2015.12.1324..
DOI: 10.1016/j.jaci.2015.12.1324
Bantz S.K., Zhu Z., Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5:202. doi: 10.4172/2155- 9899.1000202..
DOI: 10.4172/2155- 9899.1000202
Jarvis D., Newson R., Lotvall J., Hastan D., Tomassen P., Keil T., et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67:91-8. doi: 10.1111/j.1398-9995.2011.02709.x..
DOI: 10.1111/j.1398-9995.2011.02709.x
Bachert C., Gevaert P., Holtappels G., Johansson S.G., van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107:607-614. doi: 10.1067/mai.2001.112374..
DOI: 10.1067/mai.2001.112374
Kang J.W., Nahm D.H., Suh K.S., Kim H.Y., Park H.S. Local production of specific IgE antibody to house dust mite in nasal polyp tissues. J Asthma Allergy Clin Immunol. 1998;18:426-433.
Ying S., Humbert M., Meng Q., Pfister R., Menz G., Gould H.J., et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol. 2001;107:686-692. doi: 10.1067/mai.2001.114339..
DOI: 10.1067/mai.2001.114339
Zhang N., Holtappels G., Gevaert P., Patou J., Dhaliwal B., Gould H., et al. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy. 2011;66:141-148. doi: 10.1111/j.1398-9995.2010.02448.x..
DOI: 10.1111/j.1398-9995.2010.02448.x
Van Zele T., Gevaert P., Holtappels G., Beule A., Wormald P.J., Mayr S., et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125:1069-1076.e4. doi: 10.1016/j.jaci.2010.02.020..
DOI: 10.1016/j.jaci.2010.02.020
Penn R., Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21:428-432. doi: 10.2500/ajr.2007.21.3060..
DOI: 10.2500/ajr.2007.21.3060
Vennera Mdel C., Picado C., Mullol J., Alobid I., Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66:824-825. doi: 10.1136/thx.2010.152835..
DOI: 10.1136/thx.2010.152835
Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110-116.e1. doi: 10.1016/j.jaci.2012.07.047..
DOI: 10.1016/j.jaci.2012.07.047
Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110-116.e1. doi: 10.1016/j.jaci.2012.07.047..
DOI: 10.1016/j.jaci.2012.07.047
Pinto J.M., Mehta N., DiTineo M., Wang J., Baroody F.M., Naclerio R.M. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48:318-324. doi: 10.4193/rhin09.144..
DOI: 10.4193/rhin09.144
Garcia G., Magnan A., Chiron R., et al. A proofof-concept, randomized, controlled trial of omalizumab in patients with severe, difficulttocontrol, nonatopic asthma. Chest. 2013;144(2):411–419. doi: 10.1378/chest.12-1961..
DOI: 10.1378/chest.12-1961
Domingo C., Pomares X., Angril N., Rudi N., Amengual M.J., Mirapeix R.M. Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents. 2013;27(1):45–53.
Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558– 562. doi: 10.1016/s0091-6749(98)70271-4..
DOI: 10.1016/s0091-6749(98)70271-4
James C., Bernstein D.I. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017;17(1):55–59. doi: 10.1097/aci.0000000000000335..
DOI: 10.1097/aci.0000000000000335
Normansell R., Kew K.M., Bridgman A.L. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2015;(8):CD011293. doi: 10.1002/14651858. cd011293.pub2..
DOI: 10.1002/14651858. cd011293.pub2
Lambert N., Guiddir T., Amat F., Just J. Pretreatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol. 2014;25(8):829–832. doi: 10.1111/ pai.12306..
DOI: 10.1111/ pai.12306
Casale T.B., Busse W.W., Kline J.N., et al; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134–140. doi: 10.1016/j.jaci.2005.09.036..
DOI: 10.1016/j.jaci.2005.09.036
Massanari M., Nelson H., Casale T., et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125(2):383–389. doi: 10.1016/j. jaci.2009.11.022..
DOI: 10.1016/j. jaci.2009.11.022
Dantzer J.A., Wood R.A. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018;48(3):232–240. doi: 10.1111/ cea.13084..
DOI: 10.1111/ cea.13084
Incorvaia C., Mauro M., Gritti B.L., Makri E., Ridolo E. Venom immunotherapy in patients with allergic reactions to insect stings. Expert Rev Clin Immunol. 2018;14(1):53–59. doi: 10.1080/1744666x.2018.1413350..
DOI: 10.1080/1744666x.2018.1413350
Boni E., Incorvaia C., Mauro M. Dosedependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy. 2016;14:14. doi: 10.1186/s12948-016-0051-2..
DOI: 10.1186/s12948-016-0051-2
Abdel-Gadir A., Schneider L., Casini A., et al. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018;48(7):825–836. doi: 10.1111/cea.13161..
DOI: 10.1111/cea.13161
Ильина Н.И., Курбачева О.М., Павлова К.С. Эффективность аллергенспецифической иммунотерапии на фоне приема препарата Омализумаб у пациентов с атопическими заболеваниями. Вопросы современной педиатрии. 2008;7(3):44-51. Режим доступа: https://vsp.spr-journal.ru/jour/article/view/1397.https://vsp.spr-journal.ru/jour/article/view/1397
Ильина Н.И., Курбачева О.М., Павлова К.С. Эффективность аллергенспецифической иммунотерапии на фоне приема препарата Омализумаб у пациентов с атопическими заболеваниями. Вопросы современной педиатрии. 2008;7(3):44-51. Режим доступа: https://vsp.spr-journal.ru/jour/article/view/1397.https://vsp.spr-journal.ru/jour/article/view/1397
Ильина Н.И., Курбачева О.М., Павлова К.С. Возможности комбинированного применения аллерген-специфической иммунотерапии с параллельным введением антиIgE-антител в лечении пациентов с атопическими заболеваниями. Российский аллергологический журнал. 2008;2:17-27. Режим доступа: http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf.http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf
Ильина Н.И., Курбачева О.М., Павлова К.С. Возможности комбинированного применения аллерген-специфической иммунотерапии с параллельным введением антиIgE-антител в лечении пациентов с атопическими заболеваниями. Российский аллергологический журнал. 2008;2:17-27. Режим доступа: http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf.http://rusalljournal.ru/journal/pdf/2008/2008-2/2-2008.pdf
Shah A., Panjabi C. Allergic bronchopulmonary aspergillosis: a perplexing clinical entity. Allergy Asthma Immunol Res. 2016;8:282- 97. doi: 10.4168/aair.2016.8.4.282..
DOI: 10.4168/aair.2016.8.4.282
Agarwal R., Chakrabarti A., Shah A., Gupta D., Meis J.F., Guleria R., et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43:850-873. doi: 10.1111/cea.12141..
DOI: 10.1111/cea.12141
Agarwal R., Aggarwal A.N., Gupta D., Jindal S.K. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009;13:936-944.
Hoyt A.E., Borish L., Gurrola J., Payne S. Allergic fungal rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4:599-604. doi: 10.1016/j.jaip.2016.03.010..
DOI: 10.1016/j.jaip.2016.03.010
Humbert M., Bousquet J., Bachert C., Palomares O., Pfister P., Kottakis I., Jaumont X., Thomsen S.F., Papadopoulos N.G. IgEMediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. J Allergy Clin Immunol Pract. 2019;7(5):1418- 1429. doi: 10.1016/j.jaip.2019.02.030..
DOI: 10.1016/j.jaip.2019.02.030
Eigenmann P.A., Beyer K., Wesley Burks A., et al. New visions for food allergy: an iPAC summary and future trends. Pediatr Allergy Immunol. 2008;19(19):26-39. doi: 10.1111/j.1399-3038.2008.00765.x..
DOI: 10.1111/j.1399-3038.2008.00765.x
Sicherer S.H. Food allergy. Mt Sinai J Med. 2011;78:683-696. doi: 10.1002/msj.20292..
DOI: 10.1002/msj.20292
Sicherer S.H., Sampson H.A. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133:291-307; quiz 8. doi: 10.1016/j.jaci.2013.11.020..
DOI: 10.1016/j.jaci.2013.11.020
Tordesillas L., Berin M.C., Sampson H.A. Immunology of food allergy. Immunity. 2017;47:32-50. doi: 10.1016/j.immuni.2017.07.004..
DOI: 10.1016/j.immuni.2017.07.004
Mills E.N., Mackie A.R., Burney P., Beyer K., Frewer L., Madsen C., et al. The prevalence, cost and basis of food allergy across Europe. Allergy. 2007;62:717-722. doi: 10.1111/j.1398-9995.2007.01425.x..
DOI: 10.1111/j.1398-9995.2007.01425.x
Wang J., Liu A.H. Food allergies and asthma. Curr Opin Allergy Clin Immunol. 2011;11:249- 254. doi: 10.1097/aci.0b013e3283464c8e..
DOI: 10.1097/aci.0b013e3283464c8e
Begin P., Chinthrajah R.S., Nadeau K.C. Oral immunotherapy for the treatment of food allergy. Hum Vaccin Immunother. 2014;10:2295-2302. doi: 10.4161/hv.29233..
DOI: 10.4161/hv.29233
Nadeau K.C., Kohli A., Iyengar S., DeKruyff R.H., Umetsu D.T. Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy. Immunol Allergy Clin North Am. 2012;32:111-133. doi: 10.1016/j.iac.2011.11.004..
DOI: 10.1016/j.iac.2011.11.004
Umetsu D.T, Rachid R., Schneider L.C. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J. 2015;8:20. doi: 10.1186/s40413-015-0070-3..
DOI: 10.1186/s40413-015-0070-3
Andorf S., Purington N., Block W.M., Long A.J., Tupa D., Brittain E., et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3:85-94. doi: 10.1016/s2468-1253(17)30392-8..
DOI: 10.1016/s2468-1253(17)30392-8
Labrosse R., Graham F., Des Roches A., Begin P. The use of omalizumab in food oral immunotherapy. Arch Immunol Ther Exp (Warsz). 2017;65:189-99. doi: 10.1007/s00005-016-0420-z..
DOI: 10.1007/s00005-016-0420-z
Frischmeyer-Guerrerio P.A., Masilamani M., Gu W., Brittain E., Wood R., Kim J., et al. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2017;140:1043-1053.e8. doi: 10.1016/j.jaci.2017.03.028..
DOI: 10.1016/j.jaci.2017.03.028
Savage J.H., Courneya J.P., Sterba P.M., Macglashan D.W., Saini S.S., Wood R.A. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130:1123-1129.e2. doi: 10.1016/j.jaci.2012.05.039..
DOI: 10.1016/j.jaci.2012.05.039
Rafi A., Do L.T., Katz R., Sheinkopf L.E., Simons C.W., Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc. 2010;31:76-83. doi: 10.2500/aap.2010.31.3304..
DOI: 10.2500/aap.2010.31.3304
Sampson H.A., Leung D.Y., Burks A.W., Lack G., Bahna S.L., Jones S.M., et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309-13010. e1. doi: 10.1016/j.jaci.2011.01.051..
DOI: 10.1016/j.jaci.2011.01.051
Leung D.Y., Sampson H.A., Yunginger J.W., Burks A.W. Jr, Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986- 993. doi: 10.1056/nejmoa022613..
DOI: 10.1056/nejmoa022613
Galli E., Gianni S., Auricchio G., Brunetti E., Mancino G., Rossi P. Atopic dermatitis and asthma. Allergy Asthma Proc. 2007;28:540-3. doi: 10.2500/aap2007.28.3048..
DOI: 10.2500/aap2007.28.3048
Eichenfield L.F., Hanifin J.M., Beck L.A., Lemanske R.F. Jr, Sampson H.A., Weiss S.T., et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics. 2003;111:608-616. doi: 10.1542/peds.111.3.608..
DOI: 10.1542/peds.111.3.608
van der Hulst A.E., Klip H., Brand P.L. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120:565-569. doi: 10.1016/j.jaci.2007.05.042..
DOI: 10.1016/j.jaci.2007.05.042
Celakovská J., Buka C.J. The severity of atopic dermatitis evaluated with the SCORAD index and the occurrence of bronchial asthma and rhinitis, and the duration of atopic dermatitis. Allergy Rhinol (Providence). 2016;7:8-13. doi: 10.2500/ar.2016.7.0144..
DOI: 10.2500/ar.2016.7.0144
Iyengar S.R., Hoyte E.G., Loza A., Bonaccorso S., Chiang D., Umetsu D.T., et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162:89-93. doi: 10.1159/000350486..
DOI: 10.1159/000350486
Heil P.M., Maurer D., Klein B., Hultsch T., Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebocontrolled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8:990-998. DOI: 10.1111/j.1610-0387.2010.07497.x..
DOI: 10.1111/j.1610-0387.2010.07497.x
Holm J.G., Agner T., Sand C., Thomsen S.F. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18-26. doi: 10.1111/ijd.13353..
DOI: 10.1111/ijd.13353
Chan S., Cornelius V., Chen T., Radulovic S., Wan M., Jahan R., et al. Atopic Dermatitis AntiIgE Paediatric Trial (ADAPT): the role of antiIgE in severe paediatric eczema: study protocol for a randomised controlled trial. Trials. 2017;18:136. doi: 10.1186/s13063-017-1809-7..
DOI: 10.1186/s13063-017-1809-7
Sheinkopf L.E., Rafi A.W., Do L.T., Katz R.M., Klaustermeyer W.B. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530-537. doi: 10.2500/aap.2008.29.3160..
DOI: 10.2500/aap.2008.29.3160